Autoimmune Myelopathy Panel, CSF
Ordering Recommendation
Use to evaluate rapid-onset neurologic symptoms associated with spinal cord dysfunction.
Testing in both serum and CSF is recommended to maximize diagnostic yield; refer to Autoimmune Myelopathy Panel, Serum (3006208) for serum testing.
New York DOH Approval Status
Specimen Required
CSF
Transfer three 1 mL CSF aliquots to ARUP standard transport tubes. (Min: 0.5 mL/aliquot)
Frozen
Fluid other than CSF. Grossly hemolyzed specimens
After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 month (avoid repeated freeze/thaw cycles)
Methodology
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody/Semi-Quantitative Indirect Fluorescent Antibody (IFA)/Qualitative Immunoblot/Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
Performed
Varies
Reported
3-10 days
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
mGluR1 Ab IgG CBA-IFA Screen, CSF | Less than 1:1 | |
Glutamic Acid Decarboxylase Antibody CSF | 0.0-5.0 IU/mL | |
NMO/AQP4 Ab IgG CBA-IFA Screen, CSF | Less than 1:1 | |
GABA-BR Ab IgG CBA-IFA Screen, CSF | Less than 1:1 | |
CV2 Ab IgG CBA-IFA Screen, CSF | Less than 1:1 | |
DPPX Ab IgG CBA-IFA Screen, CSF | Less than 1:1 | |
SOX1 Antibody, IgG by Immunoblot, CSF | Negative | |
Amphiphysin Antibody, CSF | Negative | |
Paraneoplastic Abs (PCCA/ANNA) IgG, CSF | None Detected |
Interpretive Data
Refer to report
Laboratory Developed Test (LDT)
Note
If CV2 CSF antibody IgG is positive, then titer will be added. Additional charges apply.
PCCA/ANNA antibody IgG is screened by IFA. If the IFA screen is indeterminate, then a Neuronal Nuclear Antibodies (Hu, Ri, Yo, and Tr/DNER) IgG by Immunoblot will be performed. If the IFA screen is positive at 1:10 or greater, then a PCCA/ANNA antibodies titer and Neuronal Nuclear Antibodies (Hu, Ri, Yo, Tr/DNER) IgG by Immunoblot will be performed. Additional charges apply.
If DPPX CSF antibody IgG by IFA is positive, then titer will be added. Additional charges apply.
If GABA-BR CSF antibody IgG is positive, then titer will be added. Additional charges apply.
If AQP4/NMO CSF antibody IgG by IFA is positive, then titer will be added. Additional charges apply.
If mGluR1 CSF antibody IgG by IFA is positive, then titer will be added. Additional charges apply.
Hotline History
Hotline History
CPT Codes
86341; 86052; 84182 x2; 86255 x5; if reflexed add 84182 x4; 86256 per titer
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
2010842 | Paraneoplastic Abs (PCCA/ANNA) IgG, CSF | 14247-1 |
2011700 | NMO/AQP4 Ab IgG CBA-IFA Screen, CSF | 46718-3 |
3001268 | GABA-BR Ab IgG CBA-IFA Screen, CSF | 82984-6 |
3002259 | CV2 Ab IgG CBA-IFA Screen, CSF | 53707-6 |
3002789 | Glutamic Acid Decarboxylase Antibody CSF | 42501-7 |
3002904 | SOX1 Antibody, IgG by Immunoblot, CSF | 94383-7 |
3004511 | Amphiphysin Antibody, CSF | 57750-2 |
3004513 | DPPX Ab IgG CBA-IFA Screen, CSF | 94283-9 |
3006040 | mGluR1 Ab IgG CBA-IFA Screen, CSF | 93500-7 |
Aliases
- DPPX
- AGNA
- Amphiphysin
- ANNA
- Anti-glial nuclear antibody
- Anti-neuronal nuclear antibody
- AQP4
- Aquaporin 4
- Contactin-associated protein-like-2
- CRMP-5
- CV2
- Dipeptidyl aminopeptidase-like protein 6
- GAD65
- Glutamic acid decarboxylase
- Hu
- metabotropic glutamate receptor 1
- mGluR1
- Myelopathy
- Neuromyelitis optica
- NMO
- NMOSD
- Paraneoplastic myelopathy
- PCA
- PCCA
- Purkinje cell cytoplasmic antibody
- Ri
- Yo